Producer
AstraZeneca
Global pharmaceutical company. Originator of Symbicort (budesonide/formoterol, pMDI and Turbuhaler DPI), Pulmicort (budesonide Turbuhaler), and Breztri. Owns proprietary Turbuhaler DPI device. Manufactures at Södertälje, Sweden (API/Turbuhaler) and Dunkirk, France (pMDI fill). In Phase III clinical trials reformulating Symbicort with HFO-1234ze in partnership with Honeywell.
0
Inputs supplied
0
Goods downstream
2
Facilities
0
Stories
Where they make it
2 facilities
AstraZeneca Dunkirk pMDI Fill and Finish Facility →
FRHauts-de-France · Manufacturing
Fill and finish facility for Symbicort pMDI production. Part of AstraZeneca European manufacturing network. Dunkirk, Northern France.
AstraZeneca Södertälje Manufacturing Site →
SEStockholm County · Manufacturing
Listed manufacturer of Symbicort Turbuhaler (budesonide/formoterol). Key site for Turbuhaler DPI devices and budesonide API. Södertälje, Sweden.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Respiratory & Immunology
25%Oncology (Tagrisso, Imfinzi, Lynparza)
42%Cardiovascular, Renal & Metabolism
20%Vaccines & Immune Therapies
13%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
AstraZeneca was primarily a respiratory and cardiovascular pharmaceutical company in 2020; by 2022-2023 it had become the most widely distributed COVID-19 vaccine manufacturer globally AND the largest or second-largest oncology pharmaceutical company by revenue. The AZD1222 COVID vaccine — developed with the Jenner Institute at Oxford University using a chimpanzee adenovirus vector — was licensed to Serum Institute of India (world's largest vaccine manufacturer by volume) for developing-country production 'at cost' with no profit margin; approximately 3 billion doses were manufactured globally, making it the most widely administered COVID vaccine by total dose count. AstraZeneca's COVID vaccine role required building manufacturing partnerships and regulatory relationships in countries (India, Brazil, South Korea, Thailand) that AZ had no previous vaccine manufacturing history in. Simultaneously, Tagrisso (osimertinib for EGFR-mutated lung cancer) grew from a Phase III asset to AZ's largest single product at USD 5.7B revenue — making a respiratory drug company the dominant player in targeted lung cancer therapy, connecting respiratory medicine to oncology through organ system.
AstraZeneca PLC ↗Origin2023
AstraZeneca was formed in 1999 from the merger of Astra AB (Sweden, founded 1913) and Zeneca Group (UK, spun off from ICI in 1993). The Swedish Astra heritage is dominant in AZ's respiratory product identity: Astra scientists synthesized budesonide (inhaled corticosteroid) in 1972, which became Pulmicort — for decades the world standard for inhaled corticosteroid therapy. Astra also invented the Turbuhaler dry powder inhaler device (1988 commercial launch) — the first 'breath-actuated' DPI that delivers powder without a propellant or bulky inhalation device. The Turbuhaler was a watershed in inhaler technology. The UK Zeneca heritage contributed oncology: Zeneca had developed tamoxifen (breast cancer), anastrozole (Arimidex), and a pipeline that eventually led to Tagrisso, Lynparza, and Imfinzi — the oncology portfolio that now comprises ~40% of AZ's revenue. A Swedish respiratory drug company merged with a British agrochemical-turned-oncology company; the resulting merged entity accidentally became the most valuable oncology pharmaceutical company in the world by the 2020s.
AstraZeneca PLC ↗